Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Edith Brutcher"'
Autor:
Lisa Weiss, Edith Brutcher, Yue-Yun To, Miao-Jen Wang, Sara Hamilton, Jane Koh, Hiu Tung Leung, Huanyu Zhao, Carmen Fuertes, Karen Julien, Megumi Mori, Holly DiFebo, Yun Shen, Aralee Galway, Marina Tschaika, Jocelyn Teo, Yoon Jin Noh
Publikováno v:
The Oncologist
Background CheckMate 040 assessed the efficacy and safety of nivolumab in patients with advanced hepatocellular carcinoma (HCC). Understanding the safety profile of nivolumab is needed to support the management of treatment‐related adverse events (
Autor:
Christina Wu, Zhengjia Chen, Ganji Purnachandra Nagaraju, Chao Zhang, Walid L. Shaib, Edith Brutcher, Olatunji B. Alese, Meredith Renfroe, Hyun Soo Kim, Bassel F. El-Rayes
Publikováno v:
Cancer. 124:1992-2000
Background Neuroendocrine tumors (NETs) metastasize to the liver. Everolimus and selective internal radioembolization (SIRT) are approved treatments. Pasireotide is a somatostatin analogue with an affinity for somatostatin receptors 1, 2, 3, and 5. E
Autor:
Lauren M. Postlewait, Volkan Adsay, Bassel F. El-Rayes, Cecilia G. Ethun, Zhengjia Chen, Charles A. Staley, Edith Brutcher, Juan M. Sarmiento, Shishir K. Maithel, David A. Kooby
Publikováno v:
Journal of Surgical Oncology. 114:336-341
Background Standard adjuvant treatment for pancreatic adenocarcinoma (PDAC) is gemcitabine [Gem(CONKO-001: Gem vs. placebo DFS:13.4 vs. 6.7 mo; P
Autor:
Walid L. Shaib, Edith Brutcher, Sungjin Kim, Jonathan Rock, Kavya Krishna, Zhengjia Chen, Michael Goodman, Samih Abdel-Missih, Shishir K. Maithel, Tanios Bekaii-Saab, Bassel F. El-Rayes, Charles Iii Staley
Publikováno v:
Cancer Research and Treatment : Official Journal of Korean Cancer Association
Purpose Appendiceal tumors are a heterogeneous group of diseases that include typical neuroendocrine tumors (TNET), goblet cell carcinoids (GCC), and atypical GCC. Atypical GCC are classified into signet-ring cell cancers (SRCC) and poorly differenti
Autor:
Hyun S, Kim, Walid L, Shaib, Chao, Zhang, Ganji Purnachandra, Nagaraju, Christina, Wu, Olatunji B, Alese, Zhengjia, Chen, Edith, Brutcher, Meredith, Renfroe, Bassel F, El-Rayes
Publikováno v:
Cancer. 124(9)
Neuroendocrine tumors (NETs) metastasize to the liver. Everolimus and selective internal radioembolization (SIRT) are approved treatments. Pasireotide is a somatostatin analogue with an affinity for somatostatin receptors 1, 2, 3, and 5. Everolimus a
Autor:
Walid L. Shaib, Jerome C. Landry, David A. Kooby, Bassel F. El-Rayes, Shishir K. Maithel, Zhengjia Chen, John S. Kauh, Sungjin Kim, Edith Brutcher, Rahul Sharma
Publikováno v:
Journal of Surgical Oncology. 109:556-560
Background Ampullary (AMP-A) and duodenal adenocarcinomas (DA) are rare tumors. The literature regarding treatment and outcome is very limited. The objective of this project is to compare the outcomes of AMP-A and DA. Methods The records for AMP-A an
Autor:
Lauren M, Postlewait, Cecilia G, Ethun, David A, Kooby, Juan M, Sarmiento, Zhengjia, Chen, Charles A, Staley, Edith, Brutcher, Volkan, Adsay, Bassel, El-Rayes, Shishir K, Maithel
Publikováno v:
Journal of surgical oncology. 114(3)
Standard adjuvant treatment for pancreatic adenocarcinoma (PDAC) is gemcitabine [Gem(CONKO-001: Gem vs. placebo DFS:13.4 vs. 6.7 mo; P 0.001; OS:22.8 vs. 20.2 mo; P = 0.01)]. Addition of cisplatin (Cis) to Gem has resulted in increased PFS for advanc
Autor:
Walid L, Shaib, Rahul, Sharma, Edith, Brutcher, Sungjin, Kim, Shishir K, Maithel, Zhengjia, Chen, David A, Kooby, John, Kauh, Jerome, Landry, Bassel F, El-Rayes
Publikováno v:
Journal of surgical oncology. 109(6)
Ampullary (AMP-A) and duodenal adenocarcinomas (DA) are rare tumors. The literature regarding treatment and outcome is very limited. The objective of this project is to compare the outcomes of AMP-A and DA.The records for AMP-A and DA patients betwee